Study of infliximab for children and teens with IBD
Part of Digestive system clinical trials.
This trial is looking at children and teenagers with Crohn's disease or ulcerative colitis who are starting a biologic medicine called infliximab. It aims to learn more about how this treatment works in young patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 18 years old.
- You have been diagnosed with Crohn's disease or ulcerative colitis (a type of inflammatory bowel disease).
- You are about to start treatment with infliximab (a biologic medicine).
- You (or your parent/guardian) must agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called infliximab, given as an injection under the skin, to see how the body processes it in people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). It may help find the best dose for your condition.
This study tests if a special diet (called CDED) combined with infliximab (a biologic drug) is more effective than infliximab alone for children with newly diagnosed or relapsed moderate-to-severe Crohn’s disease. It aims to improve gut healing and reduce inflammation.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study tests whether combining infliximab (a biologic medicine that reduces inflammation) with azathioprine (an immune-suppressing drug) is safe and effective for children with moderate to severe Crohn's disease who haven't tried these medicines before.
Hear when a new IBD (Inflammatory Bowel Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.